Anticancer Bioscience has a strong Intellectual Property (IP) position and is taking a robust approach to protect its patent estate.
Our patent estate comprises applications for methods covering its platform technology, its therapeutic targets and composition of chemical matter/combinations for potential drug interventions.
We have an exclusive pipeline agreement with MBICR and any patents around synthetic lethality or other cancer breakthroughs developed at the J. Michael Bishop Institute of Cancer Research are transferred to ACB which thus owns commercialized rights.
